Study summary

Cabozantinib slowed advanced adrenal cancer in a small trial

Cabozantinib trial · 18 people · Published April 2024, Lancet Oncology

6months median before the cancer grew

What was tested

Cabozantinib, a targeted pill, in advanced adrenocortical carcinoma at MD Anderson. No comparison group.

What they found

Median time before the cancer grew was 6 months.
Serious side effects occurred in 61%, mostly lab changes and high blood pressure.

What it means

Led to a national trial combining cabozantinib with immunotherapy.

Lancet Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.